J&J Unit Slapped With $4M Verdict Over Topamax Birth Defects

Law360, New York (October 31, 2013, 6:06 PM EDT) -- A Philadelphia jury on Wednesday hit Janssen Pharmaceuticals Inc. with a $4 million verdict in a lawsuit that alleged its epilepsy drug Topamax caused birth defects.

A state court jury found that Janssen, a Johnson & Johnson unit, failed to adequately warn physicians and health care providers of the extent of the risk of birth defects stemming from the use of Topamax, and that the company’s negligence was a substantial factor in causing plaintiff April Czimmer’s son’s cleft palate.

Czimmer alleged in a 2011 complaint that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.